Angiodysplasia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Nikita Singh (talk | contribs) |
Nikita Singh (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Angiodysplasia}} | {{Angiodysplasia}} | ||
{{CMG}} {{AE}} {{NKS}} | {{CMG}} {{AE}} {{NKS}} | ||
==Agiodysplasia cost-effectiveness of therapy== | ==Agiodysplasia cost-effectiveness of therapy== | ||
Revision as of 07:34, 15 October 2021
|
Angiodysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiodysplasia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Angiodysplasia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Angiodysplasia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nikita Singh, M.D.[2]
Agiodysplasia cost-effectiveness of therapy
Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most cost-effective endoscopic therapy for bleeding lesions. Pharmacological therapies are also cost-effective for patients with significant co-morbidities who cannot undergo endoscopic therapy.[1][2]
References
- ↑ Olmos JA, Marcolongo M, Pogorelsky V, Herrera L, Tobal F, Dávolos JR (2006). "Long-term outcome of argon plasma ablation therapy for bleeding in 100 consecutive patients with colonic angiodysplasia". Dis Colon Rectum. 49 (10): 1507–16. doi:10.1007/s10350-006-0684-1. PMID 17024322.
- ↑ Sami SS, Al-Araji SA, Ragunath K (2014). "Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management". Aliment Pharmacol Ther. 39 (1): 15–34. doi:10.1111/apt.12527. PMID 24138285.